Vaxxas Home

Vaxxas Nanopatch™ Technology

Vaccine Application System
Nanopatch Microprojections
Pages > News > News

Vaxxas

News

News and Publications

Revolutionizing Vaccination - Vaxxas Secures Funding to Advance Clinical Development

February 17, 2015

Channel 7 spotlights Vaxxas' Nanopatch™ vaccine platform. Watch the video here.

More...

Vaxxas Raises A$25 Million [US$20 Million] in Series B Venture Financing

February 9, 2015

Cambridge, Mass., USA, and Brisbane, Queensland, Australia
Funds to advance a series of clinical programs and develop a pipeline of new vaccine products for major diseases.
Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced it has secured equity funding of A$25 million [US$20 million] from new and existing investors.

More...

Research Project on Advancing Nanopatch™ Technology for Polio Vaccine Delivery

September 16, 2014

BRISBANE, QUEENSLAND, AUSTRALIA, AND CAMBRIDGE, MASS., USA
WHO to provide funding of project, as part of its efforts to secure lasting polio-free world
Vaxxas, a biotechnology company commercializing a novel vaccine delivery platform, today announced the initiation of a research project to evaluate Vaxxas' proprietary Nanopatch™ platform for delivery of polio vaccine.

More...

Nanopatch™ Platform Overview on World Economic Forum Technology Pioneers 2015

August 26, 2014

Vaxxas CTO and Founder, Professor Mark Kendall, describes the Nanopatch™ vaccine platform in a review recorded as part of the Vaxxas selection as a World Economic Forum Technology Pioneer for 2015.

More...

Vaxxas Selected as World Economic Forum Technology Pioneer 2015

August 26, 2014

BRISBANE, QUEENSLAND, AUSTRALIA, AND CAMBRIDGE, MASS., USA
Vaxxas, a biotechnology company commercializing a novel vaccine delivery platform, has been named a 2015 Technology Pioneer by the World Economic Forum. Vaxxas is one of 24 emerging technology companies from around the world and across all industries recognized for their potential to transform the future of business and society.

Read this story...

Vaxxas Recognized as 2013 BioSpectrum Asia-Pacific Emerging Company of the Year

March 18, 2013

Vaxxas announced today it has received the BioSpectrum Asia-Pacific Emerging Company of the Year Award. The award recognizes Vaxxas for the potential of its needle-free Nanopatch™ platform to enhance delivery efficiency and improve effectiveness of a wide range of vaccines.

Read this story...

Vaxxas Recognized as 2012 Janssen AusBiotech Emerging Company of the Year

October 31, 2012

Vaxxas, a biotechnology company commercializing a novel vaccine-delivery platform that activates immunological cells immediately below the surface of the skin, announced today it has received the 2012 Janssen AusBiotech Emerging Company of the Year Award. This award recognizes Vaxxas' significant technological achievements, and efforts to foster growth in the biotechnology industry.

Read this story...

Needle-less technology partners with Merck

October 09, 2012

HERALD SUN
Vaccines given with a painless skin patch rather than needles are a step closer after Australian innovators secured a deal with international vaccine manufacturer Merck.

Read this story...

Merck Acquires License for Experimental Skin-Patch Immunization

October 09, 2012

BLOOMBERG
Merck & Co. (MRK), the maker of the Gardasil cervical cancer vaccine, will work with Vaxxas Pty to develop a skin-patch delivery system for immunizations, the Brisbane, Australia-based company said.

Read this story...

Vaxxas Entices Merck to Try Needle-Free Vaccine Technique

October 09, 2012

XCONOMY
Scientists have been trying for a long time to deliver vaccines without needles. Now the Boston biotech community is importing a new take on this idea from Australia that’s also caught the eye of Merck.

Read this story...

Vaxxas initiates program with Merck to optimize delivery of vaccines

October 09, 2012

Vaxxas, a biotechnology company commercializing a novel vaccine delivery platform, today announced the initiation of a research collaboration with Merck, known as MSD outside the United States and Canada. The collaboration will evaluate Vaxxas' proprietary Nanopatch™ platform that induces robust immune system activation by targeting vaccine to the abundant immunological cells immediately below the surface of the skin.

Read this story...

Vaxxas appoints David Hoey as company's first CEO

October 09, 2012

Vaxxas, a biotechnology company commercializing a novel vaccine-delivery platform that activates immunological cells immediately below the surface of the skin, announced today that David Hoey has been appointed as Chief Executive Officer. He has also been appointed to the company's Board of Directors.

Read this story...

ABC science TV news program "Catalyst" spotlights Vaxxas' Nanopatch™

August 30, 2012

Leading Australian science TV news magazine spotlights Vaxxas' Nanopatch™ vaccine platform, discussing its genesis and potential to revolutionize the use and applicability of vaccines globally here.

Read this story...

Rolex Laureate for Nanopatch Researcher's Pioneering Efforts

June 14, 2012

Biomedical engineer Professor Mark Kendall is one of only five recipients of a prestigious Rolex Laureate, recognising pioneering efforts to expand knowledge and improve human life. A researcher at the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, Prof. Kendall is the driving force behind development of needle-free vaccine delivery device the Nanopatch™.

Read this story...

Vaxxas co-founder named as one of Australia's top 100 engineers

June 2012

Professor Mark Kendall is named by Engineers Australia as one of Australia's most influencial engineers - listed in the top 100 engineers. Further information can be found here.

Read this story...

Vaccine Industry Excellence Awards

April 17, 2012

WASHINGTON, DC, USA and BRISBANE, QUEENSLAND, AUSTRALIA
The $15m syndicated investment in Vaxxas Pty Ltd, developers of the Nanopatch™, a new needle-free vaccine delivery system, was judged the Best Venture Capital Investment at the 2012 Vaccine Industry Excellence Awards, held at the World Vaccine Congress in Washington, DC last week.

Read this story...

BRW Start-up of the Year

February 13, 2012

BRW this week announced the 10 best start-ups for 2011, and OneVentures investment Vaxxas was amongst the 10... In an effort to support and promote the efforts of the founders of start-up businesses, BRW has produced a list of the top start-ups of 2011. We hope their success stories will inspire and help others who are contemplating stepping away from the comfort of a salaried position and launching a business of their own.

Read this story...

Australian Innovation Challenge Awards

December 8, 2011

PLAN to deliver vaccines to millions of the world's poor through biomedical patches the size of postage stamps was named the overall winner at The Australian Innovation Challenge awards in Brisbane.

Read this story...

Eureka Prize

September 20, 2011

It takes more than just one person to develop a scientific breakthrough – or claim the most prestigious award in Australian science. Just ask Australian Institute for Bioengineering and Nanotechnology Professor Mark Kendall, who was last night awarded the Eureka Prize for Research by an Interdisciplinary Team.

Read this story...

Vaxxas kick starts with $15 million venture capital investment

August 2, 2011

Vaxxas founded, raises US$16.46 million (AU$15 million) in Series A financing round from leading venture investors. Please see full press release here (PDF).

Download PDF

Prof. Mark Kendall discusses the mission and vision for Vaxxas

August 2011

Prof. Mark Kendall discusses the mission and vision for Vaxxas as the company is launched with its initial US$16.46 million (AU$15 million) Series A venture investment. To view web video, please go to Prof. Kendall's web page here.

Read this story...

Publications

 

Click here for a list of publications.

List of publications